UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure

Clinical research in cardiology, 2023-07, Vol.112 (7), p.901-910

2023

Volltextzugriff (PDF)

Renal Dysfunction Is a Strong and Independent Risk Factor for Mortality and Cardiovascular Complications in Renal Transplantation

American journal of transplantation, 2005-08, Vol.5 (8), p.1986-1991

2005

Volltextzugriff (PDF)

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation

Nephrology, dialysis, transplantation, 2005-05, Vol.20 (5), p.974-980

2005

Volltextzugriff (PDF)

Fluvastatin treatment is not associated with an increased incidence of cancer

International journal of clinical practice (Esher), 2006-09, Vol.60 (9), p.1028-1034

2006

Volltextzugriff (PDF)

Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy

Circulation. Heart failure, 2017-11, Vol.10 (11)

2017

Volltextzugriff (PDF)

Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial

Transplantation, 2005-05, Vol.79 (9), p.1160-1163

2005

Volltextzugriff (PDF)

Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure

European journal of heart failure, 2023-09, Vol.25 (9), p.1584-1592

2023

Volltextzugriff (PDF)

The Relationship between LVEF and Cardiovascular Outcomes Following Hospitalization for Heart failure: Insights from the RELAX-AHF-2 Trial

Journal of cardiac failure, 2019-08, Vol.25 (8), p.S55-S55

2019

Volltextzugriff (PDF)

New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

European journal of heart failure, 2017-06, Vol.19 (6), p.718-727

2017

Volltextzugriff (PDF)

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

European heart journal, 2013-10, Vol.34 (40), p.3117-3127

2013

Volltextzugriff (PDF)

Renal transplant dysfunction—importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality

Nephrology, dialysis, transplantation, 2006-08, Vol.21 (8), p.2282-2289

2006

Volltextzugriff (PDF)

Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al

ESC Heart Failure, 2018-12, Vol.5 (6), p.1069-1071

2018

Volltextzugriff (PDF)

Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: A pooled analysis of thirty clinical trials

Clinical therapeutics, 2007-09, Vol.29 (9), p.1987-2000

2007

Volltextzugriff (PDF)

ORIGINAL PAPER: Fluvastatin treatment is not associated with an increased incidence of cancer

International journal of clinical practice (Esher), 2006-09, Vol.60 (9), p.1028

2006

Volltextzugriff (PDF)

Fluvastatin treatment is not associated with an increased incidence of cancer: FLUVASTATIN AND RISK OF CANCER

International journal of clinical practice (Esher), 2006-09, Vol.60 (9), p.1028-1034

2006

Volltextzugriff (PDF)

NO DETRIMENTAL EFFECT ON RENAL FUNCTION DURING LONG-TERM USE OF FLUVASTATIN

Transplantation, 2004-07, Vol.78, p.327

2004

Volltextzugriff (PDF)

Mo-P5:352 Risk reduction and safety of fluvastatin in patients with the metabolic syndrome

Atherosclerosis. Supplements, 2006, Vol.7 (3), p.123-123

2006

Volltextzugriff (PDF)

W16-P-031 Fluvastatin safety profile in patients with low levels of ldl cholesterol in the Lescol® intervention prevention study

Atherosclerosis. Supplements, 2005-04, Vol.6 (1), p.108-108

2005

Volltextzugriff (PDF)

W16-O-001 Fluvastatin additional benefit beyond LDL-C reduction: A comparison of cardiovascular events risk in patients with the same level of on treatment LDL

Atherosclerosis. Supplements, 2005-04, Vol.6 (1), p.99-99

2005

Volltextzugriff (PDF)

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial

JAMA : the journal of the American Medical Association, 2013-03, Vol.309 (11), p.1125

2013

Volltextzugriff (PDF)

Drug Discovery for Kinetoplastid Diseases: Future Directions

ACS infectious diseases, 2019-02, Vol.5 (2), p.152-157

2019

Volltextzugriff (PDF)

Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)

European journal of heart failure, 2011-01, Vol.13 (1), p.100-106

2011

Volltextzugriff (PDF)

RENAL TRANSPLANT FUNCTION AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE AND MORTALITY AND FOR ALL CAUSE MORTALITY IN RENAL TRANSPLANTATION - EXPERIENCE FROM THE ALERT TRIAL

Transplantation, 2004-07, Vol.78, p.57-58

2004

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(14)
Female
(8)
Male
(8)
Middle Aged
(8)
Biological And Medical Sciences
(7)
Cardiac & Cardiovascular Systems
(7)
Cardiovascular System & Cardiology
(7)
Medical Sciences
(7)
Mortality
(6)
Heart Failure
(5)
Heart Failure - Drug Therapy
(5)
Medicine
(5)
Risk Factors
(5)
Adult
(4)
Cardiology. Vascular System
(4)
Cardiovascular Disease
(4)
Double-Blind Method
(4)
Fatty Acids, Monounsaturated - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure

Renal Dysfunction Is a Strong and Independent Risk Factor for Mortality and Cardiovascular Complications in Renal Transplantation

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation

Fluvastatin treatment is not associated with an increased incidence of cancer

Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy

Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial

Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure

The Relationship between LVEF and Cardiovascular Outcomes Following Hospitalization for Heart failure: Insights from the RELAX-AHF-2 Trial

New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Renal transplant dysfunction—importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality

Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al

Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: A pooled analysis of thirty clinical trials

ORIGINAL PAPER: Fluvastatin treatment is not associated with an increased incidence of cancer

Fluvastatin treatment is not associated with an increased incidence of cancer: FLUVASTATIN AND RISK OF CANCER

NO DETRIMENTAL EFFECT ON RENAL FUNCTION DURING LONG-TERM USE OF FLUVASTATIN

Mo-P5:352 Risk reduction and safety of fluvastatin in patients with the metabolic syndrome

W16-P-031 Fluvastatin safety profile in patients with low levels of ldl cholesterol in the Lescol® intervention prevention study

W16-O-001 Fluvastatin additional benefit beyond LDL-C reduction: A comparison of cardiovascular events risk in patients with the same level of on treatment LDL

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial

Drug Discovery for Kinetoplastid Diseases: Future Directions

Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)

RENAL TRANSPLANT FUNCTION AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE AND MORTALITY AND FOR ALL CAUSE MORTALITY IN RENAL TRANSPLANTATION - EXPERIENCE FROM THE ALERT TRIAL

Suchergebnisse filtern